Gara Jalqabaatti › Baayyee Ulfaataa › North Carolina › Havelock
Qorannoo klinikaalii Baayyee Ulfaataa Havelock, NC keessatti
Qorannoo 17 Baayyee Ulfaataa f Havelock fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Namoota walitti qabaa jiraSadarkaa 2
- Centricity Research - Morehead city /ID# 283264, Morehead City · Miili 15 fagaatti
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Namoota walitti qabaa jiraSadarkaa 3
- West Clinical Research, Morehead City · Miili 15 fagaatti
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Namoota walitti qabaa jiraSadarkaa 3
- Lucas Research, Inc, Morehead City · Miili 15 fagaatti
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Namoota walitti qabaa jiraSadarkaa 3
- West Clinical Research, Morehead City · Miili 15 fagaatti
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
Namoota walitti qabaa jiraSadarkaa 3
- Carteret Medical Group, Morehead City · Miili 15 fagaatti
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Namoota walitti qabaa jiraSadarkaa 3
- West Clinical Research, Morehead City · Miili 15 fagaatti
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Namoota walitti qabaa jiraSadarkaa 2
- Lucas Research, Inc, Morehead City · Miili 15 fagaatti
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Namoota walitti qabaa jiraSadarkaa 3
- AURORA-1 Clinical Site, Morehead City · Miili 15 fagaatti
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Namoota walitti qabaa jiraSadarkaa 3
- AURORA-2 Clinical Site, Morehead City · Miili 15 fagaatti
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Namoota walitti qabaa jiraSadarkaa 3
- Centricity Research Morehead City Multispeciality, Morehead City · Miili 15 fagaatti
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
Namoota walitti qabaa jiraSadarkaa 2
- Lucas Research, Inc., Morehead City · Miili 15 fagaatti
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Namoota walitti qabaa jiraSadarkaa 3Hojjettoota fayyaa simatamoo
- ACCOMPLISH-2 Research Site, Morehead City · Miili 15 fagaatti
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Namoota walitti qabaa jiraSadarkaa 2
- Lucas Research, Inc, Morehead City · Miili 15 fagaatti
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Namoota walitti qabaa jiraSadarkaa 3
- Kailera Clinical Site, Morehead City · Miili 15 fagaatti
Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
Namoota walitti qabaa jiraSadarkaa 3
- Kailera Clinical Site, Morehead City · Miili 15 fagaatti
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
Namoota walitti qabaa jiraSadarkaa 3
- West Clinical Research, Morehead City · Miili 15 fagaatti
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Namoota walitti qabaa jiraSadarkaa 3
- Centricity Research Morehead City Specialty, Morehead City · Miili 15 fagaatti
Qorannoo Baayyee Ulfaataa magaalota biroo keessatti
- San Antonio, TXQorannoo 34
- Houston, TXQorannoo 33
- Chicago, ILQorannoo 28
- Orlando, FLQorannoo 27
- Las Vegas, NVQorannoo 23
- Miami, FLQorannoo 23
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 20
- New York City, NYQorannoo 19
- Jacksonville, FLQorannoo 19
- Washington, DCQorannoo 19
- Austin, TXQorannoo 18
Qorannoo biroo Havelock keessatti
- ObesityQorannoo 17
- Sukkaraa Gosa 2Qorannoo 13
- Dhukkubaa Harkaa SteatoticQorannoo 5
- Dhiibbaa Dhiigaa Ol'aanaaQorannoo 3
- Dhukkubaa GravesQorannoo 3
- Dhukkubaa AlzheimerQorannoo 3
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.